Plum Alley Ventures

Plum Alley Ventures operates from New York with a focused mission: backing women founders and gender-diverse teams building frontier technologies and medical breakthroughs. The firm closed its inaugural $22M venture fund in 2023, deploying capital across 14 portfolio companies in sectors ranging from CRISPR therapeutics to autonomous retail to sustainable aviation fuel.

Unlike generalist funds that dabble in diversity, Plum Alley has been at this work since 2011 when the firm first launched as Plum Alley Inc. The 2024 launch of Plum Alley Ventures Company expanded their platform specifically for domain-expert venture fund managers who share the conviction that diverse founding teams produce outsized returns in deep tech.

Founders seeking Plum Alley capital should understand this is not a check-writing exercise. The firm's three General Partners—Deborah Jackson, Andrea Turner Moffitt, and Avantika Daing—bring operational experience and expect portfolio companies to demonstrate technical rigor alongside commercial potential. The firm targets companies where all holdings are in STEM fields with at least one female executive.

Plum Alley's thesis rests on a straightforward market observation: women founders receive roughly 2% of venture funding despite founding companies at comparable rates to men. That systematic underinvestment creates opportunity for investors willing to do the work identifying exceptional teams overlooked by mainstream VC.

The firm publishes investment check sizes of $750K to $3M per transaction, positioning them squarely in Series A territory where the funding gap for women-led companies is most acute. Seed-stage capital has proliferated; Series A has not, and Plum Alley targets that specific moment in a company's trajectory.

With $100M deployed into women founders in STEM fields since their founding—impacting an estimated 100 million people worldwide—Plum Alley has established itself as a credible partner for serious founders building transformative companies in healthcare, biotechnology, climate technology, and frontier systems.

Plum Alley's investment thesis centers on a clear conviction: technological advances in hardware, software, computing, data, and medicine have been nothing short of miraculous over the past decade, and those same forces will define the next twenty years. The firm exists to ensure women founders and gender-diverse teams capture their rightful share of that value creation.

The firm's General Partners look for founders with vision, credentials, and a demonstrable history of success—who have distinct and powerful convictions about their companies and the future. Technical depth matters enormously; Plum Alley expects portfolio companies to possess defensible intellectual property, strong research validation, and clear paths to commercialization.

Sector concentration spans biotechnology and CRISPR therapeutics (Mammoth Biosciences), women's health biotechnology (Gameto), autonomous electric freight (Einride), autonomous retail (AiFi), sustainable protein alternatives (Air Protein, Helaina), agricultural technology (InnerPlant), medical imaging (Openwater), wastewater epidemiology (Biobot Analytics), air quality monitoring (Aclima), and industrial systems (Arix Technologies).

Geographic proximity to world-class research institutions drives the New York location, giving Plum Alley direct access to the academic and medical communities generating the foundational science for many portfolio companies. The firm looks for companies emerging from or adjacent to top-tier research environments.

Plum Alley's thesis explicitly rejects the notion that diversity is merely a nice-to-have. The firm cites evidence that women-led companies generate strong returns when funded—the underinvestment is a market inefficiency, not a signal of inferior opportunity. Backing exceptional women founders building transformative companies in deep tech and life sciences is not philanthropy; it is disciplined venture investing.

Plum Alley closed its inaugural $22M venture fund in 2023, deploying across 14 companies in their first 12 months of active deployment. This pace reflects a conviction that exceptional founders building in their target sectors have been systematically underfunded by mainstream venture.

The fund's concentrated portfolio approach—fewer but deeper investments per company—allows Plum Alley's three General Partners to provide meaningful operational support rather than spreading attention thin across dozens of holdings. Each portfolio company receives strategic guidance from partners with direct domain expertise.

Market conditions have not dampened Plum Alley's deployment velocity. The firm has continued making new investments and supporting existing portfolio companies through follow-on rounds, maintaining conviction in frontier tech and medical breakthroughs even as consumer-facing sectors contracted.

The firm's approach to due diligence reflects their technical focus: expect rigorous questioning around intellectual property position, research validation, regulatory pathway (particularly for healthcare and biotech companies), and path to commercialization. Plum Alley brings in technical advisors when evaluating complex deep tech opportunities.

Founders report that Plum Alley's investment process typically spans 3-5 weeks from initial meeting to term sheet, though complex deals in biotechnology or medical devices may require additional time for technical due diligence. The firm prefers to lead or co-lead rounds, asserting conviction through meaningful check size rather than symbolic participation.

Plum Alley's 14-company portfolio demonstrates the breadth of frontier technology worth pursuing with women-led teams. Mammoth Biosciences represents the firm's conviction in CRISPR therapeutics—the company's gene-editing platform has attracted attention from major pharmaceutical partners seeking next-generation precision medicine capabilities.

Gameto addresses a market gap the firm identified early: women's health biotechnology has been chronically underfunded despite massive unmet need. Gameto is building reproductive longevity solutions that could reshape how medicine approaches female aging.

Einride, a Swedish company in the portfolio, exemplifies the international scope of Plum Alley's ambitions. The autonomous electric freight company is reimagining logistics with a full-stack approach to electric and autonomous trucking that has attracted fleet operators globally.

AiFi brings autonomous retail technology to brick-and-mortar locations, competing in a space where computer vision and edge computing converge. The company's partnerships with major retailers demonstrate commercial validation in a category that has seen significant investment churn.

Air Protein and Helaina represent Plum Alley's conviction in sustainable food systems. Air Protein produces meat alternatives using proprietary fermentation technology; Helaina focuses on food science and immune proteins that could transform nutritional ingredients.

Biobot Analytics gained particular prominence during the pandemic—the company's wastewater epidemiology technology provided real-time population-level disease surveillance that municipal governments and health systems actively used for public health decision-making.

Other portfolio holdings span InnerPlant (AgTech sensors), One Health (canine cancer precision medicine), Ashvattha Therapeutics (targeted disease treatment), Openwater (medical imaging), Ketos (water testing), Aclima (air quality monitoring), and Arix Technologies (industrial corrosion robotics).

Plum Alley evaluates potential investments through two lenses: founder quality and technical differentiation. The firm expects founders to demonstrate deep domain expertise, previous successes, and the intellectual honesty to acknowledge what they do not yet know.

Technical differentiation must be defensible. The firm looks for proprietary technology, exclusive partnerships, or other moats that protect market position over time. In biotechnology and deep tech specifically, intellectual property portfolios are scrutinized for breadth, novelty, and freedom to operate.

Market opportunity must be large and growing. Plum Alley resists companies pursuing small total addressable markets regardless of technical elegance. The firm wants to back companies that can reach meaningful scale—hundreds of millions in potential revenue—not interesting science projects that will require perpetual grant funding.

The founding team composition matters, but not in a formulaic way. Plum Alley backs companies where at least one female founder or executive holds a meaningful equity stake and operates role. The firm does not require a female CEO, but expects gender-diverse leadership teams with genuine operational roles—not token appointments.

Evidence of product-market fit strengthens any pitch. Plum Alley wants to see customer traction, strong unit economics where applicable, and a clear path to the next inflection point. Early-stage companies should demonstrate that paying customers exist and that the product solves a real problem at a price customers will pay.

Scalability is non-negotiable. The firm prefers companies whose business models can grow efficiently without proportional cost increases. Software characteristics—margins that expand as the business scales—appeal to Plum Alley's return requirements.

Warm introductions from the entrepreneurial ecosystem remain Plum Alley's preferred entry point. The firm is most likely to meet with founders who come recommended by portfolio CEOs, other investors who have backed the founder in prior rounds, or members of the academic and research community who understand the technical merits of the work.

Cold submissions through the Plum Alley website are accepted but face higher bars. If pursuing this route, founders should ensure the pitch deck is polished, the technical differentiation is immediately apparent, and the team composition clearly demonstrates why this specific group is best positioned to execute on the opportunity.

The application should lead with the problem and the technical solution—not the market size slide that every VC sees repeatedly. Plum Alley's partners have deep technical backgrounds; they will probe the science and expect founders to defend their assumptions rigorously.

When preparing for a meeting, founders should anticipate questions about the intellectual property strategy, regulatory pathway (particularly for healthcare and biotech), the competitive landscape in granular technical detail, and realistic financial projections grounded in evidence rather than optimistic assumptions.

Follow-up after initial meetings is expected but professional. Plum Alley typically requires several weeks for investment decisions given the technical due diligence involved. Maintain communication through milestone updates without being pushy—the firm values founders who understand professional boundaries.

Building a long-term relationship with Plum Alley—even without immediate investment—can pay dividends. The firm's network extends across 36 companies and multiple cohorts of investors. Even if your current round does not result in an investment, Plum Alley may facilitate introductions to other investors who are a better fit for your stage or sector.

Frontier technology and deep science companies face particular scrutiny around financial projections. Plum Alley's partners will challenge assumptions about burn rate, runway, and path to profitability or the next funding round. Founders must demonstrate they understand their business's financial mechanics at a granular level.

Technical founders often underestimate the importance of investor-ready financials when raising capital. Deep tech companies typically have longer paths to revenue than software companies, making realistic scenario planning and honest discussion of capital requirements essential to credibility with Plum Alley.

Working with a fractional CFO can meaningfully strengthen a pitch. Professional financial guidance helps founders build accurate projections, prepare due diligence materials that survive rigorous questioning, and confidently communicate the capital efficiency story that Plum Alley expects from well-managed deep tech companies.

Unit economics matter even for pre-revenue companies. Plum Alley wants to understand the assumptions underlying customer acquisition costs, lifetime value, and the incremental economics of scaling the business. Deep tech companies with defensible margins at eventual scale will find receptive audiences.

Key performance indicators vary by sector, but founders should be able to explain the metrics that matter most to their business, why those metrics matter, and how trends in those metrics should be interpreted. Plum Alley will probe your understanding of your own business, not just the technical merits.

The firm's three General Partners provide operational support to portfolio companies—but that support is most effective when founders already have strong financial foundations. Demonstrating financial literacy sets the stage for a productive partnership rather than a relationship where Plum Alley must teach fundamentals.

Plum Alley's conviction that diverse founding teams generate superior returns in deep tech represents a thesis the firm has validated across 14 portfolio companies in their inaugural fund. For founders building in frontier technology and medical breakthroughs—particularly those who have faced systemic underfunding—Plum Alley offers not just capital but a partnership model built on genuine technical understanding and operational commitment.

Exploring other venture capital firms targeting women-led companies or frontier technology? Our comprehensive collection of VC firm reviews covers hundreds of investors across all stages and sectors.

Each review provides detailed information about investment criteria, portfolio companies, check sizes, and strategies for securing funding. Whether you are raising seed capital for an early-stage company or Series A for a more mature business, you will find relevant insights in our VC firm guides.

Finding the right investor for your startup is crucial to your success. Take time to research potential investors and understand their specific investment thesis before reaching out—generic pitches to generalist funds rarely succeed.